Cargando…

Clinical features and prognosis of MPO-ANCA and anti-GBM double-seropositive patients

BACKGROUND: Several lines of evidence implicate that there are distinct differences between patients with myeloperoxidase (MPO)-antineutrophil cytoplasmic antibody (ANCA) and anti-glomerular basement membrane (GBM) antibody double-seropositive patients (DPPs) and single-positive patients. Hence, we...

Descripción completa

Detalles Bibliográficos
Autores principales: Hu, Xueling, Shen, Chanjuan, Meng, Ting, Ooi, Joshua D., Eggenhuizen, Peter J., Zhou, Ya-ou, Luo, Hui, Chen, Jin-biao, Lin, Wei, Gong, Yizi, Xiong, Qi, Xu, Jia, Liu, Ning, Xiao, Xiangcheng, Tang, Rong, Zhong, Yong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9648717/
https://www.ncbi.nlm.nih.gov/pubmed/36389826
http://dx.doi.org/10.3389/fimmu.2022.991469
_version_ 1784827637131116544
author Hu, Xueling
Shen, Chanjuan
Meng, Ting
Ooi, Joshua D.
Eggenhuizen, Peter J.
Zhou, Ya-ou
Luo, Hui
Chen, Jin-biao
Lin, Wei
Gong, Yizi
Xiong, Qi
Xu, Jia
Liu, Ning
Xiao, Xiangcheng
Tang, Rong
Zhong, Yong
author_facet Hu, Xueling
Shen, Chanjuan
Meng, Ting
Ooi, Joshua D.
Eggenhuizen, Peter J.
Zhou, Ya-ou
Luo, Hui
Chen, Jin-biao
Lin, Wei
Gong, Yizi
Xiong, Qi
Xu, Jia
Liu, Ning
Xiao, Xiangcheng
Tang, Rong
Zhong, Yong
author_sort Hu, Xueling
collection PubMed
description BACKGROUND: Several lines of evidence implicate that there are distinct differences between patients with myeloperoxidase (MPO)-antineutrophil cytoplasmic antibody (ANCA) and anti-glomerular basement membrane (GBM) antibody double-seropositive patients (DPPs) and single-positive patients. Hence, we conducted a retrospective study from a single center in China to analyze the clinical and pathological features, and prognosis of DPPs. METHODS: 109 patients with MPO-ANCA-associated vasculitis (MPO-AAV), 20 DPPs and 23 patients diagnosed with anti-GBM disease from a large center in China were included in this study. The ratio of patients with renal biopsy in three groups were 100%, 50% and 100%, respectively. Their clinical and pathological characteristics, and outcomes were analyzed. The intensity of immune deposits in the kidney at diagnosis was detected by immunofluorescence (IF). Furthermore, multivariate Cox hazard model analysis was used to assess the clinical and histological predictors of end-stage renal disease (ESRD) and death for DPPs. RESULTS: In our study, we found that patients in the DPPs group were older than the other two groups (p = 0.007, MPO-AAV vs. DPPs; p < 0.001, DPPs vs. anti-GBM). The DPPs group had a higher value of serum creatinine (p = 0.041) and lower estimated glomerular filtration rate (eGFR) (p = 0.032) compared with MPO-AAV patients. On the contrary, the DPPs group had a lower serum creatinine (p = 0.003) compared with patients with anti-GBM group. The proportion of patients with cardiac system involvement in the DPPs group was higher than anti-GBM patients (p = 0.014). Cellular crescents could be generally observed in renal biopsy of DPPs and patients with anti-GBM glomerulonephritis. In addition, Bowman’s capsule rupture was more common in DPPs than MPO-AAV patients (p = 0.001). MPO-AAV had a better renal and overall survival outcome than DPPs (p < 0.001). There was no significant difference of renal and overall survival outcome between DPPs and patients with anti-GBM disease. The incidence of ESRD in DPPs was negatively associated with lymphocyte count (HR 0.153, 95% CI 0.027 to 0.872, p = 0.034) and eGFR (HR 0.847, 95% CI 0.726 to 0.989, p = 0.036). Elevated serum creatinine was confirmed as a risk factor of both renal (HR 1.003, 95% CI 1.000 to 1.005, p = 0.019) and patient survival in DPPs (HR1.461, 95% CI 1.050 to 2.033, p = 0.024). CONCLUSION: In summary, compared with anti-GBM disease, DPPs tended to involve multi-organ damage rather than limited to the kidney. It is highlighted that serologic DPPs have a worse renal and patient prognosis than MPO-AAV. Moreover, we found that the risk factors of renal survival of DPPs include low lymphocyte count, elevated serum creatinine and reduced eGFR, and serum creatinine can predict patient survival.
format Online
Article
Text
id pubmed-9648717
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-96487172022-11-15 Clinical features and prognosis of MPO-ANCA and anti-GBM double-seropositive patients Hu, Xueling Shen, Chanjuan Meng, Ting Ooi, Joshua D. Eggenhuizen, Peter J. Zhou, Ya-ou Luo, Hui Chen, Jin-biao Lin, Wei Gong, Yizi Xiong, Qi Xu, Jia Liu, Ning Xiao, Xiangcheng Tang, Rong Zhong, Yong Front Immunol Immunology BACKGROUND: Several lines of evidence implicate that there are distinct differences between patients with myeloperoxidase (MPO)-antineutrophil cytoplasmic antibody (ANCA) and anti-glomerular basement membrane (GBM) antibody double-seropositive patients (DPPs) and single-positive patients. Hence, we conducted a retrospective study from a single center in China to analyze the clinical and pathological features, and prognosis of DPPs. METHODS: 109 patients with MPO-ANCA-associated vasculitis (MPO-AAV), 20 DPPs and 23 patients diagnosed with anti-GBM disease from a large center in China were included in this study. The ratio of patients with renal biopsy in three groups were 100%, 50% and 100%, respectively. Their clinical and pathological characteristics, and outcomes were analyzed. The intensity of immune deposits in the kidney at diagnosis was detected by immunofluorescence (IF). Furthermore, multivariate Cox hazard model analysis was used to assess the clinical and histological predictors of end-stage renal disease (ESRD) and death for DPPs. RESULTS: In our study, we found that patients in the DPPs group were older than the other two groups (p = 0.007, MPO-AAV vs. DPPs; p < 0.001, DPPs vs. anti-GBM). The DPPs group had a higher value of serum creatinine (p = 0.041) and lower estimated glomerular filtration rate (eGFR) (p = 0.032) compared with MPO-AAV patients. On the contrary, the DPPs group had a lower serum creatinine (p = 0.003) compared with patients with anti-GBM group. The proportion of patients with cardiac system involvement in the DPPs group was higher than anti-GBM patients (p = 0.014). Cellular crescents could be generally observed in renal biopsy of DPPs and patients with anti-GBM glomerulonephritis. In addition, Bowman’s capsule rupture was more common in DPPs than MPO-AAV patients (p = 0.001). MPO-AAV had a better renal and overall survival outcome than DPPs (p < 0.001). There was no significant difference of renal and overall survival outcome between DPPs and patients with anti-GBM disease. The incidence of ESRD in DPPs was negatively associated with lymphocyte count (HR 0.153, 95% CI 0.027 to 0.872, p = 0.034) and eGFR (HR 0.847, 95% CI 0.726 to 0.989, p = 0.036). Elevated serum creatinine was confirmed as a risk factor of both renal (HR 1.003, 95% CI 1.000 to 1.005, p = 0.019) and patient survival in DPPs (HR1.461, 95% CI 1.050 to 2.033, p = 0.024). CONCLUSION: In summary, compared with anti-GBM disease, DPPs tended to involve multi-organ damage rather than limited to the kidney. It is highlighted that serologic DPPs have a worse renal and patient prognosis than MPO-AAV. Moreover, we found that the risk factors of renal survival of DPPs include low lymphocyte count, elevated serum creatinine and reduced eGFR, and serum creatinine can predict patient survival. Frontiers Media S.A. 2022-10-27 /pmc/articles/PMC9648717/ /pubmed/36389826 http://dx.doi.org/10.3389/fimmu.2022.991469 Text en Copyright © 2022 Hu, Shen, Meng, Ooi, Eggenhuizen, Zhou, Luo, Chen, Lin, Gong, Xiong, Xu, Liu, Xiao, Tang and Zhong https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Immunology
Hu, Xueling
Shen, Chanjuan
Meng, Ting
Ooi, Joshua D.
Eggenhuizen, Peter J.
Zhou, Ya-ou
Luo, Hui
Chen, Jin-biao
Lin, Wei
Gong, Yizi
Xiong, Qi
Xu, Jia
Liu, Ning
Xiao, Xiangcheng
Tang, Rong
Zhong, Yong
Clinical features and prognosis of MPO-ANCA and anti-GBM double-seropositive patients
title Clinical features and prognosis of MPO-ANCA and anti-GBM double-seropositive patients
title_full Clinical features and prognosis of MPO-ANCA and anti-GBM double-seropositive patients
title_fullStr Clinical features and prognosis of MPO-ANCA and anti-GBM double-seropositive patients
title_full_unstemmed Clinical features and prognosis of MPO-ANCA and anti-GBM double-seropositive patients
title_short Clinical features and prognosis of MPO-ANCA and anti-GBM double-seropositive patients
title_sort clinical features and prognosis of mpo-anca and anti-gbm double-seropositive patients
topic Immunology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9648717/
https://www.ncbi.nlm.nih.gov/pubmed/36389826
http://dx.doi.org/10.3389/fimmu.2022.991469
work_keys_str_mv AT huxueling clinicalfeaturesandprognosisofmpoancaandantigbmdoubleseropositivepatients
AT shenchanjuan clinicalfeaturesandprognosisofmpoancaandantigbmdoubleseropositivepatients
AT mengting clinicalfeaturesandprognosisofmpoancaandantigbmdoubleseropositivepatients
AT ooijoshuad clinicalfeaturesandprognosisofmpoancaandantigbmdoubleseropositivepatients
AT eggenhuizenpeterj clinicalfeaturesandprognosisofmpoancaandantigbmdoubleseropositivepatients
AT zhouyaou clinicalfeaturesandprognosisofmpoancaandantigbmdoubleseropositivepatients
AT luohui clinicalfeaturesandprognosisofmpoancaandantigbmdoubleseropositivepatients
AT chenjinbiao clinicalfeaturesandprognosisofmpoancaandantigbmdoubleseropositivepatients
AT linwei clinicalfeaturesandprognosisofmpoancaandantigbmdoubleseropositivepatients
AT gongyizi clinicalfeaturesandprognosisofmpoancaandantigbmdoubleseropositivepatients
AT xiongqi clinicalfeaturesandprognosisofmpoancaandantigbmdoubleseropositivepatients
AT xujia clinicalfeaturesandprognosisofmpoancaandantigbmdoubleseropositivepatients
AT liuning clinicalfeaturesandprognosisofmpoancaandantigbmdoubleseropositivepatients
AT xiaoxiangcheng clinicalfeaturesandprognosisofmpoancaandantigbmdoubleseropositivepatients
AT tangrong clinicalfeaturesandprognosisofmpoancaandantigbmdoubleseropositivepatients
AT zhongyong clinicalfeaturesandprognosisofmpoancaandantigbmdoubleseropositivepatients